Method of inhibiting osteoclast activity
AssigneeImmunex Corporation
InventorsDirk M. ANDERSON, Laurent J. GALIBERT
Life of this patent
Estimating the term…
Abstract
Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.
Claims6
A method of inhibiting RANK-induced osteoclastogenesis in a patient in need thereof, comprising administering to the patient an antagonistic antibody that binds a RANKL polypeptide consisting of SEQ ID NO:8, wherein
- the patient suffers from a condition selected from the group consisting of bone cancer, multiple myeloma, melanoma and breast cancer, and
- the antibody is administered in an amount sufficient to inhibit RANK-induced osteoclastogenesis in the patient.
A method of inhibiting RANK-induced osteoclastogenesis in a patient in need thereof, the method comprising administering to the patient an antagonistic antibody that binds a RANKL polypeptide consisting of SEQ ID NO:8, wherein
- the patient suffers from a condition selected from the group consisting of squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancer, head and neck cancer and renal cancer,
- the antibody is administered in an amount sufficient to inhibit RANK-induced osteoclastogenesis in the patient.
Dependencies are inferred from the claim text.